Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. for securities fraud, following significant stock drops attributed to potential violations of federal securities laws [1][2]. Company Overview - Stride, Inc. is an education technology company that provides an online platform for students across the U.S. [3]. Allegations - The lawsuit claims that Stride inflated enrollment numbers by retaining "ghost students," failed to comply with employee background checks and licensure laws, and provided a poor customer experience leading to higher withdrawal rates and lower conversion rates [3][4]. Stock Performance - On September 14, 2025, Stride's stock dropped by $18.60, or over 11%, from $158.36 to $139.76 per share following the fraud allegations [4]. - On October 28, 2025, Stride admitted to poor customer experiences, resulting in an estimated 10,000-15,000 fewer enrollments, causing the stock to plummet by $83.48, or more than 54%, from $153.53 to $70.05 per share [5]. Legal Proceedings - Investors have until January 12, 2026, to request to lead the case in the U.S. District Court for the Eastern District of Virginia [2].

NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Inspire, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/inspire-medical- ...

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [1][2][3]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [3]. - The company conducted Phase 3 VELA trials for sonelokimab, an investigational therapeutic aimed at treating moderate to severe hidradenitis suppurativa [3]. Clinical Data and Claims - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated higher clinical responses for patients and a competitive edge for sonelokimab [4]. - The company asserted that the Nanobody structure of SLK provided beneficial differences compared to traditional monoclonal antibody treatments [4]. Allegations and Stock Impact - Allegations suggest that the clinical data and Nanobody structure did not provide a superior clinical benefit over competitors, raising doubts about the drug's regulatory approval and commercial viability [5]. - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock plummeted nearly 90%, from $61.99 to $6.24 per share [6].

Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - Synopsys, Inc. provides design automation software products used for designing and testing integrated circuits. Its Design IP segment, which supplies pre-designed silicon components to semiconductor companies, has been the fastest-growing segment, increasing from 25% of revenue in 2022 to 31% in 2024 [4]. Financial Performance - In Q3 2025, Synopsys reported a revenue of $425.9 million for its Design IP segment, reflecting a 7.7% year-over-year decline. The net income was $242.5 million, marking a 43% year-over-year decline [6]. Stock Market Reaction - Following the release of disappointing Q3 2025 financial results, Synopsys' stock price fell from $604.37 per share on September 9, 2025, to $387.78 per share on September 10, 2025, a decline of nearly 36% [6].

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud affecting shareholders between February 23, 2022, and July 30, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit claims that Baxter's Novum LVP product had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [3]. - It is alleged that Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects [3]. - Baxter's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [3]. - The lawsuit suggests that there was an increased risk of customers being instructed to take Novum LVPs out of service and that Baxter would halt all new sales of these pumps [3]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [3]. Group 2: Next Steps for Affected Shareholders - Shareholders who suffered losses during the specified timeframe are encouraged to learn about their rights to seek recovery, with no cost or obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky LLP is highlighted as a nationally-recognized securities litigation firm with a strong track record in securing recoveries for shareholders [5]. - The firm has over 20 years of experience and has been consistently ranked among the top securities litigation firms in the United States [5].

Core Viewpoint - The Synopsys class action lawsuit alleges that the company and its executives violated the Securities Exchange Act of 1934, with claims centered around undisclosed issues affecting its financial performance and business operations [1][4]. Company Overview - Synopsys, Inc. provides electronic design automation software products used for designing and testing integrated circuits, operating in two segments: Design Automation and Design IP [3]. Allegations and Financial Impact - The lawsuit claims that Synopsys failed to disclose the negative impact of its increased focus on artificial intelligence customers on the economics of its Design IP business, leading to poor financial results [4]. - On September 9, 2025, Synopsys reported third quarter 2025 revenue of $1.740 billion, which was below its guidance of $1.755 billion to $1.785 billion, and net income of $242.5 million, marking a 43% decline from $425.9 million in the same quarter of 2024 [5]. - The Design IP segment accounted for approximately 25% of revenue, totaling $426.6 million, which represented a 7.7% year-over-year decline, with guidance indicating a potential full-year decline of at least 5% for fiscal 2025 [5].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit due to alleged false statements and misleading information regarding the launch of its Inspire V device, which has resulted in significant financial losses for investors [1][4][10]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled "City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc." and covers the period from August 6, 2024, to August 4, 2025 [1]. - Investors have until January 5, 2026, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that Inspire Medical and its executives violated the Securities Exchange Act of 1934 [1]. Group 2: Allegations Against Inspire Medical - The lawsuit claims that the launch of the Inspire V device was poorly executed, with significant surplus inventory and reluctance from providers to adopt the new treatment [4]. - It is alleged that Inspire Medical failed to complete essential tasks necessary for a successful launch, contrary to their assurances to investors [4]. - On August 4, 2025, Inspire Medical disclosed that the launch faced an "elongated timeframe" due to undisclosed challenges, including incomplete training and onboarding at implanting centers [5]. Group 3: Financial Impact - Following the negative news regarding the Inspire V launch, Inspire Medical reduced its 2025 earnings guidance by over 80% [5]. - The stock price of Inspire Medical declined by more than 32% after the announcement of these issues [5].

Core Viewpoint - Perrigo Company plc is under investigation for potential violations of federal securities laws, which may impact investors who have incurred losses [1] Investigation Details - The investigation is initiated by the Law Offices of Frank R. Cruz on behalf of investors [1] - The focus is on the company's financial disclosures and compliance with securities regulations [1] Investor Impact - Investors who lost money on Perrigo Company plc are encouraged to inquire about pursuing claims to recover their losses [1] - The investigation follows the release of Perrigo's third quarter financial results for 2025, indicating potential concerns regarding the company's financial health [1]

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. alleging securities fraud due to undisclosed material design changes to its G6 and G7 glucose monitoring devices, which posed health risks to users and increased regulatory scrutiny [3][4][5]. Summary by Sections Lawsuit Details - The lawsuit covers investors who purchased DexCom securities from July 26, 2024, to September 17, 2025, claiming that the company made misleading statements regarding the reliability and safety of its devices [3]. - Allegations include unauthorized design changes to the G6 and G7 devices, which made them less reliable and posed health risks to users [3]. Regulatory Issues - On March 7, 2025, DexCom received a warning letter from the FDA regarding manufacturing and quality management concerns, leading to a share price drop of approximately 9.15% [4]. - The FDA's warning letter, published on March 25, 2025, indicated that the G6 and G7 devices were "adulterated" due to modifications made without prior approval, causing inaccuracies that could endanger users [5]. Market Reactions - Following the FDA's warning, DexCom's share price fell by $1.77, or about 2.4%, on March 25, 2025 [5]. - On September 8, 2025, Oppenheimer downgraded DexCom's rating to "perform" from "outperform," citing concerns over the G7's accuracy, which resulted in a share price decline of approximately 3.1% [6]. - A report by Hunterbrook Media on September 18, 2025, revealed severe health risks associated with the G7 devices, leading to a significant share price drop of about 11% the following day [7].

Core Viewpoint - An amended securities class action lawsuit has been filed against CarMax, Inc., expanding the class period to include purchases made between June 20, 2025, and November 5, 2025, with a lead plaintiff deadline set for January 2, 2026 [1]. Allegations Against Defendants - The complaint alleges that during the class period, defendants made false or misleading statements and failed to disclose that CarMax's growth prospects were overstated, attributing earlier growth in the 2026 fiscal year to temporary factors related to customer behavior influenced by tariff speculation [2]. - It is claimed that the positive statements made by defendants regarding the company's business and prospects were materially misleading and lacked a reasonable basis throughout the relevant time [2]. Lead Plaintiff Process - Investors in CarMax have until January 2, 2026, to seek appointment as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or they may choose to remain absent from the class [3]. - The lead plaintiff will represent all class members in directing the litigation and is typically the investor or small group of investors with the largest financial interest [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions in various courts and has a reputation for recovering billions for victims of corporate misconduct [4].